A team of investigators led by William Dauer, MD of University of Michigan has made new discoveries about DYT6 dystonia, which affects children. DYT6 dystonia occurs when the body cannot properly produce a protein called THAP1, whose role and function in cells is unknown. Using a mouse model, Dr. Dauer and colleagues discovered that THAP1 is essential for myelination, a process during brain development that forms a protective coating around neurons.

DMRF and Cure Dystonia Now jointly supported a research investigation to explore whether a drug called AZD1446 could potentially provide relief for dystonia patients with fewer side effects than existing medications. Although AZD1446 did not demonstrate therapeutic effects in animal and cell models of DYT1 dystonia, the investigation produced important findings.

Seaman, Tom. (2017). What is Dystonia? Life impact and chronic pain treatment perspectives. Pain-Free Living, p. 49-52.

March of Dimes Canada will help residents in Calgary and British Columbia with physical disabilities to enhance their community access and participation through the Assistive Mobile Technology Initiative by providing customized tablet packages (a tablet, a stylus and a cover/case), for up to 8 residents in each location. The tablet prize package will also include a pre-paid credit card to purchase/install appropriate apps to meet their needs, for a total value of up to $1,875.